Proprio Announces Research Collaboration with NYU Grossman School of Medicine

January 21, 2021

Proprio notes that Dr. John Golfinos, the Joseph P. Ransohoff Professor and Chair of the Department of Neurosurgery, will serve as the Project Director.

Dr. Golfinos will help guide research and the development of the company’s breakthrough imaging and navigation system for neurosurgical and spinal applications.

Proprio is pleased to have one of the nation’s leading academic neurosurgery programs as a research collaborator,” said Gabriel Jones, Co-Founder and CEO of Proprio. “We believe leading programs like NYU Grossman School of Medicine can play a key role in the design of surgeon-centric products. Working with their Department of Neurosurgery will help us bring to market an imaging and navigation system that lets surgeons focus on the patient in an entirely new way.”

“Our department has long been a leader in advancing patient care through revolutionary technology and world-class surgical technique,” said Dr. Golfinos. “We’re excited about the Proprio system’s potential to greatly improve the accuracy and efficiency of complex surgeries.”

The company notes as part of the collaboration, NYU Grossman School of Medicine neurosurgery residents and research fellows will have the opportunity to work with the Proprio technology development team at Proprio’s Seattle headquarters, contributing to product requirements, testing versions of the Proprio system, providing surgical guidance on product development, and conducting clinical studies. Proprio intends to place units at NYU for in situ studies upon receiving FDA clearance.

SourceProprio

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”